Cargando…

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin

Dual and triple infections with hepatitis virus C (HCV), B (HBV) and D (HDV) frequently lead to severe liver damage. Hereby we describe a 38-year-old Caucasian male coinfected with HCV (genotype 3a), HBV [positive hepatitis B surface antigen (HbsAg) and antibody to hepatitis B core antigen; negative...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hartl, Janine, Ott, Claudia, Kirchner, Gabriele, Salzberger, Bernd, Wiest, Reiner
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications 2012
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981316/ https://www.ncbi.nlm.nih.gov/pubmed/24765463 http://dx.doi.org/10.4081/cp.2012.e64

Ejemplares similares

Chances for cure in chronic HBV/HDV coinfection
por: Iliescu, Gabriela, et al.
Publicado: (2014)

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
por: Macías, Juan, et al.
Publicado: (2015)

Genetic Variability of Hepatitis C Virus (HCV) 5’ Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin
por: Bukowska-Ośko, Iwona, et al.
Publicado: (2015)

Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study
por: Kovari, Helen, et al.
Publicado: (2015)

Hepatitis D, B and C virus (HDV/HBV/HCV) coinfection as a diagnostic problem and therapeutic challenge
por: Lorenc, Beata, et al.
Publicado: (2017)

Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Grubczak, Kamil, et al.
Publicado: (2021)

Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients
por: Schmidbauer, Caroline, et al.
Publicado: (2021)

Deciphering the Interleukin 28B Variants That Better Predict Response to Pegylated Interferon-α and Ribavirin Therapy in HCV/HIV-1 Coinfected Patients
por: de Castellarnau, Montserrat, et al.
Publicado: (2012)

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018)

Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients
por: Bedimo, Roger, et al.
Publicado: (2016)

Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
por: Tseng, Chih-Wei, et al.
Publicado: (2022)

IL28B SNP rs8099917 Is Strongly Associated with Pegylated Interferon-α and Ribavirin Therapy Treatment Failure in HCV/HIV-1 Coinfected Patients
por: Aparicio, Ester, et al.
Publicado: (2010)

Clearance of HCV by Combination Therapy of Pegylated Interferon α-2a and Ribavirin Improves Insulin Resistance
por: Kim, Hong Joo, et al.
Publicado: (2009)

Effectiveness of pegylated interferon alfa plus HAART in HIV/HBV treatment-naïve coinfected patients
por: Mata-Marín, JA, et al.
Publicado: (2010)

Standard and pegylated interferon therapy of HDV infection: A systematic review and meta- analysis
por: Alavian, Seyed-Moayed, et al.
Publicado: (2012)

Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice
por: Giersch, Katja, et al.
Publicado: (2017)

HBV and HDV: New Treatments on the Horizon
por: Zuccaro, Valentina, et al.
Publicado: (2021)

Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients
por: Hatu, Giorgiana, et al.
Publicado: (2014)

The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals
por: Vogel, M, et al.
Publicado: (2010)

Oxidative status and the response to pegylated-interferon alpha2a plus ribavirin in chronic genotype 4 HCV hepatitis
por: Ahmed, Mohammed Mahmound, et al.
Publicado: (2013)

Early optic neuropathy during pegylated alfa 2-B interferon and ribavirin HCV treatment. A case report
por: Chis, Bogdan Augustin, et al.
Publicado: (2019)

PCR-Based Molecular Diagnosis of Hepatitis Virus (HBV and HDV) in HCV Infected Patients and Their Biochemical Study
por: Riaz, Muhammad Nasir, et al.
Publicado: (2016)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
por: Cho, Hyun Chin, et al.
Publicado: (2013)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
por: Carvalho-Filho, Roberto J, et al.
Publicado: (2010)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
por: Chopra, Amit, et al.
Publicado: (2015)

Hepatitis Delta Virus: HDV-HBV Interactions
por: Sureau, Camille
Publicado: (2006)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients
por: Rivero-Juárez, Antonio, et al.
Publicado: (2012)

Predictive Factors for Sustained Virological Response after Treatment with Pegylated Interferon α-2a and Ribavirin in Patients Infected with HCV Genotypes 2 and 3
por: Niederau, Claus, et al.
Publicado: (2014)

Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment
por: Zhang, Geng-lin, et al.
Publicado: (2017)

Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability
por: Malaguarnera, Giulia, et al.
Publicado: (2016)

Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia
por: Kawaguchi, Takumi, et al.
Publicado: (2019)

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
por: Meyer, Douglas F., et al.
Publicado: (2010)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
por: Chak, Eric, et al.
Publicado: (2010)

Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
por: Aizawa, Nobuhiro, et al.
Publicado: (2013)

HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation
por: Mavilia, Marianna G., et al.
Publicado: (2018)

Prevalence of HCV and/or HBV coinfection in Iranian HIV-infected patients
por: Dehghani-Dehej, Farzaneh, et al.
Publicado: (2020)

Prevalence and characteristics of HIV/HBV and HIV/HCV coinfections in Tuscany
por: Puglia, Monia, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_or1j1k059s3u180u91ousg8osu